Modality
Cell Therapy
MOA
GLP-1/GIP
Target
FXIa
Pathway
Incretin
FSGSADHDNMOSD
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
~Dec 2021
→ ~Mar 2023
Phase 3
Jun 2023
→ May 2031
Phase 3Current
NCT04527280
348 pts·FSGS
2023-06→2031-05·Not yet recruiting
348 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-035.1y awayPh3 Readout· FSGS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Not yet…
Catalysts
Ph3 Readout
2031-05-03 · 5.1y away
FSGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04527280 | Phase 3 | FSGS | Not yet recr... | 348 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |